Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Contineum Therapeutics (CTNM) Other financing activities (2023 - 2024)

Contineum Therapeutics has reported Other financing activities over the past 2 years, most recently at $140000.0 for Q1 2024.

Quarterly results put Other financing activities at $140000.0 for Q1 2024, up 2700.0% from a year ago — trailing twelve months through Mar 2024 was $157000.0 (changed N/A YoY), and the annual figure for FY2023 was $22000.0, changed.
Other financing activities for Q1 2024 was $140000.0 at Contineum Therapeutics, up from $1000.0 in the prior quarter.
Over the last five years, Other financing activities for CTNM hit a ceiling of $140000.0 in Q1 2024 and a floor of $1000.0 in Q4 2023.